

1 **Title**

2 Is influenza B/Yamagata extinct and what public health implications could this have? An updated
3 literature review and comprehensive assessment of global surveillance databases.

4
5 **Authors**

6 Saverio Caini ¹, Adam Meijer ², Marta C. Nunes ^{3,4,5}, Laetitia Henaff ⁴, Malaika Zounon ⁴,
7 Bronke Boudewijns ¹, Marco Del Riccio ^{1,6}, John Paget ¹

8
9 ¹ Nivel (Netherlands Institute for Health Services Research), Utrecht, the Netherlands.

10 ² National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.

11 ³ Center of Excellence in Respiratory Pathogens (CERP), Hospices Civils de Lyon, Lyon,
12 France.

13 ⁴ Centre International de Recherche en Infectiologie (Team Public Health, Epidemiology and
14 Evolutionary Ecology of Infectious Diseases (PHE3ID)), Inserm U1111, CNRS UMR5308, ENS
15 de Lyon, Université Claude Bernard, Lyon 1, Lyon, France.

16 ⁵ South African Medical Research Council, Vaccines & Infectious Diseases Analytics Research
17 Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

18 ⁶ Department of Health Sciences, University of Florence, Florence, Italy.

19

20 **Corresponding author**

21 Saverio Caini

22 Netherlands Institute for Health Services Research (Nivel)

23 Otterstraat 118, 3513 CR Utrecht, the Netherlands.

24 **Email address:** s.caini@nivel.nl

25

DRAFT

26 Abstract

27 **Introduction:** Early after the start of the COVID-19 pandemic, a major drop in the number of
28 influenza B/Yamagata detections was observed globally. Given the potential public health
29 implications, particularly with regards to influenza vaccination, we conducted a systematic
30 review of influenza B/Yamagata virus circulation data from multiple complementary sources of
31 information. **Methods:** We searched articles published until 20th March 2023 in PubMed and
32 EMBASE; examined epidemiological and virological influenza data for 2020-2023 contained in
33 the publicly available WHO-FluNet and GISAID (Global Initiative on Sharing All Influenza
34 Data) global databases, or collected by the multi-national Global Influenza Hospital Surveillance
35 Network (GIHSN) study; and looked for influenza data in the webpages of respiratory viruses
36 surveillance systems from countries worldwide. **Results:** Highly consistent findings were found
37 across all sources of information, with a progressive decline of influenza B/Yamagata detections
38 from 2020 onwards across all world regions, both in absolute terms (total number of cases), the
39 positivity rate, and as a fraction of influenza B detections. Isolated influenza B/Yamagata cases
40 continue to be sporadically reported, and these are typically vaccine-derived, mistaken data
41 entries or under investigation. **Discussion:** While it is still too early to conclude that B/Yamagata
42 is (or will soon become) extinct, the current epidemiological and virological data call for a rapid
43 response in terms of influenza prevention practices, particularly regarding the formulation of
44 influenza vaccines. The current epidemiological situation is unprecedented in recent decades,
45 underlying the importance of continuously and carefully monitoring the circulation of influenza
46 viruses (as well as SARS-CoV-2 and the other respiratory viruses) in the coming years.

47 **Keywords:** Influenza virus; influenza B/Yamagata virus; surveillance; influenza vaccine.

48

49 **Introduction**

50 The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
51 and the resulting coronavirus disease (COVID-19) pandemic, including the public health
52 measures that were put in place to contain the spread of the virus, caused major disruptions to the
53 circulation of influenza [**Dhanasekaran 2022**] and most other respiratory viruses. Early in the
54 course of the COVID-19 pandemic, the circulation of seasonal influenza viruses was drastically
55 reduced, with most countries around the world reporting significant declines in influenza
56 positivity rates (and, in some cases, only sporadic detections or even none at all) over the
57 following usual epidemic periods [**Olsen 2020**]. During 2022, influenza viruses gradually
58 resumed circulation [**Merced-Morales 2022**], although it is still to be determined whether the
59 pre-2020 pattern of circulation (e.g. typical timing of start, peak, and end of seasonal epidemics)
60 and burden of disease will be restored or instead changes will persist due to the co-circulation of
61 influenza and SARS-CoV-2.

62 While much uncertainty remains and predictions are difficult to make, one aspect that
63 quickly came to the attention of the scientific community was the strong decrease in the number
64 of detections of influenza B/Yamagata cases. In the years prior to the emergence of SARS-CoV-
65 2, the B/Victoria and B/Yamagata virus lineages tended to circulate simultaneously globally, with
66 no clear or consistent pattern in the way the two lineages alternated from one season to another
67 (including mixed seasons) [**Puzelli 2019**]. Interestingly, B/Yamagata viruses were responsible for
68 a larger proportion of influenza B infections than B/Victoria globally during 2012-2017, but in
69 the last two years prior to the COVID-19 pandemic (i.e. after the major outbreak of influenza
70 B/Yamagata in 2017-2018 in large parts of the world), the B/Victoria lineage had become largely
71 prevalent, and the B/Yamagata-to-B/Victoria ratio (calculated out of all influenza B cases that

72 were characterized) dropped to 1/4.5 in 2018 and 1/19.3 in 2019 [**Zanobini 2022**]. Early in the
73 course of the COVID-19 pandemic, and even after influenza viruses started circulating again in
74 2021, B/Yamagata lineage viruses were detected in only a very few countries globally according
75 to previous reports [**Koutsakos 2021, Dhanasekaran 2022, Paget 2022**], and the question arose
76 as to whether B/Yamagata lineage viruses had gone extinct (or pushed close to extinction) by the
77 pandemic.

78 It is premature to definitely declare the extinction of the B/Yamagata lineage; as viral
79 circulation might be at low levels, sub-threshold compared to the capabilities of existing
80 surveillance systems or circulating in regions of the world currently not well covered by
81 surveillance systems (e.g. West Africa), and there remains the possibility of a resurgence of the
82 B/Yamagata lineage in the future. Indeed, it is worth mentioning that during much of the 1990s
83 the B/Victoria lineage did not circulate in most regions of the world and was primarily confined
84 to East Asia, before spreading globally again in the early 2000s [**Xu 2015**]. The current
85 epidemiological situation holds significant implications for public health, particularly regarding
86 influenza vaccination strategies [**Paget 2022, Dhanasekaran 2022**]. Since quadrivalent
87 influenza vaccines (QIVs) contain virus strains from both B lineages, the question arises as to
88 whether it is appropriate to recommend a vaccine targeting a virus that is currently not
89 circulating (regardless of cost-effectiveness considerations and potential hesitancy among the
90 population). Moreover, there is a concern that the mechanistic attenuated replication of the
91 B/Yamagata strains contained in the live attenuated influenza vaccine (LAIV), primarily
92 administered to children (e.g. UK, US and EU regions), could theoretically lead to reintroduction
93 of the haemagglutinin (HA) (and neuraminidase (NA)) genes of a potentially extinct virus
94 through reassortment with a coinfecting wildtype B/Victoria lineage virus [**Dudas 2015**].

95 Importantly, LAIV, when shedding, retains its cold-adapted nature and secondary infections after
96 vaccine-derived influenza B/Yamagata infections are unlikely and indeed have not been shown to
97 date [Vesikari 2006]. Continuous monitoring of viral circulation is therefore extraordinarily
98 important so that influenza prevention policies, especially those related to vaccine formulation
99 and composition, can be adapted and tailored to the current epidemiological landscape.

100 Here we aimed to study the circulation of B/Yamagata influenza viruses from 2020
101 onwards, in order to understand whether these viruses are extinct (or could become extinct soon)
102 and discuss what public health implications this could have. For this purpose, we conducted a
103 comprehensive and systematic review of multiple data sources pertaining to the circulation of
104 B/Yamagata influenza viruses. This updated review builds upon prior assessments while aiming
105 to have a higher degree of comprehensiveness than any previously published. To achieve this,
106 our search has been extended from global databases for influenza virological surveillance (e.g.
107 WHO-FluNet and GISAID) [Paget 2022], to include another surveillance database (GISHN),
108 biomedical literature databases (PubMed and EMBASE), as well as the webpages of national
109 surveillance systems around the world.

110

111

112 **Methods**

113 Systematic literature review

114 On March 20th, 2023, we searched PubMed and EMBASE using the following search
115 string: ((influenza OR flu) AND (Yamagata OR Victoria OR lineage OR Vic OR Yam)) OR
116 ("influenza b"). All articles published from January 1st, 2020 onwards were subjected to a multi-
117 step selection process to evaluate their eligibility for inclusion in the literature review. The
118 selection procedure consisted of an initial screening-out step in which two investigators (SC and
119 BB) independently discarded irrelevant articles based on their title and abstract, and a second
120 step in which all the articles retained after the first step by at least one of the two investigators
121 were read in full text in order to evaluate their eligibility. We did not place any language
122 restriction as long as an English title and abstract were available for the first step of the selection
123 process. Finally, we included articles focusing on influenza in which the collection of respiratory
124 specimens for influenza testing extended from at least February 28th, 2020, and in which the
125 virus lineage was determined in all or a subset of the detected influenza B cases. We excluded
126 articles in which: (a) the data collection period was entirely prior to 2020 or was not specified;
127 (b) no respiratory specimens tested positive for influenza; (c) all influenza detections were due to
128 type A viruses, or the virus type was not determined; (d) none of influenza B detections was
129 tested to determine the virus lineage; or (e) there were no original data (e.g. commentaries,
130 editorials, or letters without data). Articles that were entirely based on data from the WHO-
131 FluNet, the Global Initiative on Sharing All Influenza Data (GISAID), or the Global Influenza
132 Hospital Surveillance Network (GISHN) study were not considered, since an extensive search of
133 these databases was also conducted as part of the present study (see below). We applied no
134 restrictions in terms of study design: therefore, studies as diverse as surveillance reports,

135 hospital-based clinical studies, vaccine-effectiveness studies, and phylogenetic analysis of
136 influenza isolates (e.g. to determine their genetic and antigenic characteristics) were all
137 considered as potentially eligible for inclusion as long as they matched the criteria listed above.

138 The data extracted from each eligible study included: study country, start and end of data
139 collection, number of respiratory specimens that were collected and tested for influenza, number
140 of those testing positive for influenza and specifically for type B influenza, and, among the type
141 B influenza, the number of those that were characterized and the number that had a B/Yamagata
142 lineage.

143

144 *Influenza B/Yamagata viruses reported in the WHO-FluNet, GIHSN, and GISAID*

145 The FluNet (<https://www.who.int/tools/flunet>) is a web-based database that is coordinated
146 by the WHO and is freely available to researchers. The FluNet database contains information on
147 the weekly number of laboratory-confirmed influenza detections that are uploaded from WHO
148 regional databases or directly entered by national influenza centres (NICs) and other influenza
149 reference laboratories from 194 countries and territories (in August 2023) participating in the
150 GISRS (Global Influenza Surveillance and Response System) initiative. Information on the
151 influenza virus type is available for the vast majority of reported cases as well as the influenza A
152 virus subtype, while the proportion of influenza B cases for which the lineage is reported varies
153 considerably across countries and years [**Zanobini 2022**]. Influenza data from week 1 of 2020
154 onwards was downloaded from the FluNet on August 28th, 2023. The total number of influenza
155 B/Yamagata detections and the number per 100,000 tested specimens, total influenza cases, and
156 influenza B cases (overall and the subset of those that were characterized) were calculated for

157 each of the following five periods: 2020 weeks 1-17 (January-April), 2020 weeks 18-53 (May-
158 December), 2021, 2022, and 2023 weeks 1-33. Moreover, we collected the names of the
159 countries in which influenza B/Yamagata detections occurred in each of these five periods.

160 The GIHSN (<https://gihsn.org/>) initiative was launched in 2012 through a partnership
161 between industry, public health institutions, and sentinel hospitals in several countries around the
162 world. The overarching objective of GIHSN is to collect data on the epidemiology of severe
163 influenza, defined as a laboratory-confirmed influenza infection resulting in hospitalization, and
164 provide annual estimates of the effectiveness of the influenza vaccine in preventing influenza-
165 associated hospitalization. The GIHSN database was queried for severe influenza B/Yamagata
166 cases reported from week 1 of 2020 to week 20 of 2023, with 21 countries contributing data on
167 influenza in at least one season during this period (Brazil, Canada, China, France, India, Ivory
168 Coast, Kenya, Lebanon, Mexico, Nepal, Pakistan, Peru, Romania, Russia, Senegal, Serbia, South
169 Africa, Spain, Turkey, Ukraine, and the USA).

170 GISAID (Global Initiative on Sharing All Influenza Data; <https://gisaid.org/>) is a publicly
171 accessible repository established in 2008 to share viral genomic data for influenza (later
172 expanded to include SARS-CoV-2 and other pathogens). The GISAID database includes genetic
173 sequences for all influenza viruses as well as related epidemiological data, and access is provided
174 free-of-charge to users around the world in order to stimulate research and gain understanding on
175 how influenza viruses evolve over time and spread globally. As GISAID includes influenza virus
176 sequences from other sequence databases, such as GenBank, these other databases were not
177 queried separately. The GISAID database was queried on 9 September 2023 for all B/Yamagata
178 and B/unknown-lineage labelled sequences with a collection date from March 1st, 2020 onwards.
179 Sequences were analysed using GISAID and GenBank blast and phylogenetic analysis using

180 MEGA version 7.0.21 taking into account sequences of all available segments, and Nextclade
181 version 2.14.1 (<https://clades.nextstrain.org/>) for hemagglutinin segment assessment.

182

183 *Review of national respiratory viruses surveillance systems' webpages*

184 During May and June 2023, we searched the web pages of influenza and respiratory
185 viruses surveillance systems of the following countries: England, France, Germany, Italy,
186 Netherlands, Portugal, Russia and Spain (Europe); Argentina, Brazil, Canada, Mexico and USA
187 (Americas); China, Hong Kong, Israel, Japan and Turkey (Asia); Australia and New Zealand
188 (Oceania); and South Africa (Africa). These countries were selected due to their geographical
189 representativeness and availability of web-based surveillance reports. Extracted information was
190 the number of respiratory specimens tested for influenza, as well as the number of influenza
191 detections, overall and by virus type (A and B); if available for influenza B viruses, the virus
192 lineage (Victoria, Yamagata, and not characterized) was also recorded. Moreover, we retrieved
193 the available information on the main features of the surveillance system and the duration of the
194 surveillance period (i.e. whether year-round or if limited to the usual epidemic period).

195

196 **Results**

197 Literature review

198 The literature search returned 2,147 entries in PubMed and 3,983 in EMBASE. The non-
199 duplicate articles were 4,333, of which 3,746 were discarded based on the title and abstract
200 (**Figure 1**). Of the remaining 587 articles, 547 were discarded for not matching the inclusion
201 criteria (of these, 62 were not further considered since no reported influenza cases were type B),
202 7 for being based on the WHO FluNet and/or GISAID database, 3 for being previous reports
203 from the GIHSN, and 4 because of overlap with more recent and/or larger articles based on the
204 same data sources. A total of 26 articles were included in the systematic review: their main
205 characteristics are reported in **Table 1** [**Soldevila 2022, Murillo-Zamora 2021, Korsun 2021,**
206 **Panatto 2021, Pablo-Marcos 2020, Miron 2021, Hu 2021, Omer 2022, Olson 2022, Auvinen**
207 **2022, Kuzmanovska 2021, Wagatsuma 2022, Heinzinger 2021, Rios-Silva 2022,**
208 **Suntronwong 2021, da Costa 2022, Melidou 2020, Huang 2022, O'Neill 2022, Kolosova**
209 **2022, Peck 2023, Chon 2023, Merced-Morales 2022, Melidou 2022, Sominina 2022, Song**
210 **2022**]. Europe was the most represented area (12 articles, of which 2 reported findings from
211 multiple countries in the WHO European Region), followed by Asia (n=6), North America (n=5),
212 and Oceania and South America (n=1 each). In addition, the paper by O'Neill et al. reported
213 influenza positive samples coming from fourteen countries in Oceania, Asia, and Africa during
214 2020-2021, that were subtyped at the WHO CCRRI (Collaborating Centre for Reference and
215 Research for Influenza) in Melbourne [**O'Neill 2022**].

216 In **Table 1**, studies were ordered according to the start and the end of the observation
217 period. In two articles, data collection began several years before the start of the COVID-19
218 pandemic [**Soldevila 2022, Murillo-Zamora 2021**]: B/Yamagata viruses accounted for a large

219 proportion of all characterized influenza B-positive specimens, but since data stratified by year
220 were not available, it was not possible to assess how many of them were seen after March 1st,
221 2020. Ten studies reported data for the Northern hemisphere 2019-2020 influenza season: in only
222 two of these there were B/Yamagata detections, which represented a very minor percentage of all
223 influenza-positive specimens (1 out of 1,683 in Panatto et al, Italy [**Panatto 2021**], and 6 out of
224 28,176 in Hu et al., USA [**Hu 2021**]). In two more studies (Heinzinger et al., Germany, and Ríos-
225 Silva et al., Mexico), data collection started in 2019 and ended in 2021 or, respectively, 2022
226 [**Heinzinger 2021, Rios-Silva 2021**]: in both studies, there were no B/Yamagata detections after
227 the 2019-2020 season.

228 Three studies included data that were collected entirely in 2020: Melidou et al. analyzed
229 European surveillance data from TESSy during the weeks 1-20 of 2020 and reported a single
230 influenza B/Yamagata case (out of 1,691 influenza detections overall, of which 397 were
231 influenza B) [**Melidou 2020**], while in the other two studies, conducted in Thailand and Brazil,
232 the observation period was January-March 2020 and there were no reported B/Yamagata
233 detections [**Suntronwong 2021, da Costa 2022**]. In nine more studies, the observation period
234 started in 2020 or 2021, and ended in 2021 or 2022. In China, the proportion of influenza-
235 positive specimens reported to the Chinese National Influenza Surveillance Systems that were
236 caused by B/Yamagata lineage viruses was 0.22% in 2020 and 0.07% in 2021 [**Huang 2022**].
237 The remaining studies whose observation period started in 2020 or 2021 and ended in 2021 or
238 2022 reported no or a very limited number of influenza B/Yamagata detections, which after
239 sequencing were found to be partly linked (in Melidou et al. 2022 and Merced-Morales et al.
240 2022 [**Melidou 2022, Merced-Morales 2022**]) to vaccination with LAIV.

241 In summary, we reviewed studies published up to March 2023 and whose observation
242 period extended up to 2022, and found that B/Yamagata detections were reported only in a very
243 few countries globally (and accounting for a very minor proportion of all influenza B cases) after
244 the first few months of 2020.

245

246 WHO-FluNet, GIHSN, and GISAID

247 On August 28th, 2023, we downloaded data from the WHO-FluNet for the period from
248 week 1 of 2020 to week 33 of 2023. The database contained around 31.93 million respiratory
249 specimens and 1,998,172 million influenza detections, of which 379,699 (19.0%) were influenza
250 B viruses. Of these, 272,236 (71.7%) were not characterized, 107,048 (28.2%) were B/Victoria
251 lineage, and 415 (0.1%) were B/Yamagata lineage. The average number of influenza B/Yamagata
252 detections per 100,000 processed specimens dropped from 14.9 in the weeks 1-17 of 2020 to
253 below 0.10 in 2022 and 2023 (**Table 2**). Influenza B/Yamagata accounted for a significantly
254 greater proportion of detections during the weeks 18-52 of 2020 compared to the earlier weeks in
255 the same year. This was followed by a major drop in the frequency of influenza B/Yamagata
256 detections in 2021 and 2022 (**Table 2**): the number of influenza B/Yamagata detections dropped
257 from 364 in 2020 to 45 in 2021 and three in 2022 (two from Germany and one from North
258 Korea). In the first 33 weeks of 2023, there were 6 B/Yamagata detections globally, of which five
259 were from Cameroon and one from Cuba: this represented a slight increase compared to 2022
260 but remained well below the numbers in 2020 and 2021 (**Table 2**). In summary, the rate of
261 B/Yamagata detections entered in the WHO-FluNet database dropped significantly worldwide
262 after 2020, both in absolute terms and as a percentage of the total number of influenza and
263 influenza type B detections (**Table 2**).

264 The number of influenza detections within the *GIHSN* is reported in **Table 3**. Out of a
265 total of 8,590 influenza detections reported between January 2020 and week 27 of 2023, 2,055
266 (23.9%) were influenza B. Of the 978 influenza B viruses that were characterized, seven (0.7%)
267 were B/Yamagata, all detected in 2020 (two in France, two in Mexico, one in India and one in
268 Russia in the first three months of the year, and again one in India in week 51). No B/Yamagata
269 influenza detections were reported from 2021 onwards.

270 On September 9th, the *GISAID* database was queried for all influenza B/Yamagata and
271 B/unknown-lineage sequences with collection date from March 1st, 2020, onwards. The set of
272 B/Yamagata sequences included a total of 20 non-duplicate viruses. Collection dates were in
273 March 2020 (n=14), November 2021 (n=4, all from Kenya), June 2022 (n=1, from Greece) and
274 March 2023 (n=1, from the UK). Of these, two (from Japan, 2020, and Greece, 2022) had an HA
275 genome segment identical to that of a B/Yamagata-like vaccine strain, suggesting both were
276 vaccine-derived viruses. Of the five viruses from 2021 and 2023 only the PA (n=3) or MP (n=2)
277 segment was available. For three of the four viruses from Kenya (2021), the limited available
278 information made it difficult to determine whether they were from wildtype circulating
279 B/Yamagata lineage viruses. For the remaining virus from Kenya and the virus from UK, the MP
280 segment matched with highest rank with B/Victoria lineage viruses, suggesting that these
281 detections were incorrectly labelled B/Yamagata. The B/unknown-lineage dataset included 128
282 unique viruses. The blast and phylogenetic analysis revealed that the majority (n=111) of these
283 were wildtype B/Victoria and 7 were derived from the study published in 2023 by Aslam et al.
284 on historic B viruses for influenza vaccine virus construction [**Aslam 2023**]. Of the remaining 10
285 viruses, two collected in the USA in 2021 and one from South Korea with data collection in 2020
286 were highly likely LAIV derived. Finally, seven waste water specimens collected in March 2020

287 in New York had partial PB1 sequences similar to 2007/2008 B/Yamagata lineage viruses,
288 however, no sequences of other segments were available for definitive assessment. In
289 conclusion, no sequences of wildtype viruses of the B/Yamagata lineage with a collection date
290 after March 2020 have been uploaded to GISAID and GenBank, including the viruses reported
291 as B/Yamagata lineage to FluNet and GIHSN after March 2020 (of note, therefore, for these later
292 viruses there was no objective assessment possible whether these viruses were wildtype or
293 vaccine-derived).

294

295 *Review of national respiratory viruses' surveillance systems' webpages*

296 The number of influenza B/Yamagata detections reported by country and period is shown
297 in **Table 4**, alongside with details of the surveillance system in which each case was observed
298 and overall number of influenza cases reported. After week 35 of 2020, 11 B/Yamagata
299 detections were reported: one in Australia (week 37-38 of 2020), nine in the USA (weeks 44-49
300 of 2021) and an additional case in the USA in week 46 of 2021. No B/Yamagata were reported
301 during 2022 and 2023 until the time of our search in June 2023.

302

303 To summarize the findings, we present the countries in which the last B/Yamagata
304 detections (from any of the sources that we explored) was reported in 2023 (n = 2), 2022 (n = 3),
305 or 2021 (n=9) in **Figure 2**. In all the remaining world countries, there were no B/Yamagata
306 detections after 2020.

307

308

309 Discussion

310 The early claims that the influenza B/Yamagata lineage may have gone extinct in the
311 aftermath of the COVID-19 pandemic quickly raised the attention of policymakers (e.g. WHO)
312 and vaccine manufacturers, as well as epidemiologists and researchers, due to the important
313 implications this would have on the formulation and development of both inactivated and
314 attenuated influenza vaccines. Given the enormous public health relevance and the need for solid
315 and constantly updated epidemiological data, we undertook an extensive review of the available
316 evidence on the topic, which covered multiple complementary sources of information and was
317 therefore intended to be as comprehensive as possible.

318 Considering all of the collected information, the different sources investigated are
319 concordant in showing that the number of influenza B/Yamagata viruses detections has declined
320 considerably and progressively over the last 3.5 years (i.e. from the onset of the COVID-19
321 pandemic) compared with the pre-pandemic period, both in absolute terms (i.e. number of
322 detections) and in terms of the positivity rate or as a fraction of the total number of influenza B
323 detections. After the 2009 H1N1 influenza pandemic, influenza B viruses had resumed
324 circulation causing about a quarter of all influenza cases globally on average [**Zanobini 2022**].
325 Following the major B/Yamagata outbreak that started in 2017 and involved large parts of the
326 world, however, the circulation of B/Yamagata viruses had fallen considerably (they accounted
327 for only one twentieth of all influenza B cases in 2018-2019 [**Zanobini 2022**]): this may help
328 explain (together with the lack of known zoonotic or environmental reservoirs) why it is the only
329 respiratory virus that has been pushed towards extinction by the emergence of SARS-CoV-2.
330 Indeed, only a few detected B/Yamagata cases were reported in 2022-2023, but since the
331 different world areas are unevenly covered by respiratory virus surveillance systems, some

332 caution is warranted regarding whether the B/Yamagata lineage is actually extinct. However, the
333 current epidemiological situation, with the rapid global disappearance (and potential extinction)
334 of an influenza B virus lineage, is unprecedented since influenza B viruses split into two lineages
335 in the early 1980s. In the 1990s, the B/Victoria lineage had practically disappeared from most
336 world regions (including Europe and North America), but viral circulation endured in populous
337 East Asia, so it was plausible to expect that it would re-emerge globally at some point (as it
338 happened in 2001-2002) [Xu 2015, Ikonen 2005]. Today, the protracted and nearly undetectable
339 viral circulation of B/Yamagata influenza viruses (including in East Asia) makes it much more
340 likely that we are on the verge of B/Yamagata extinction, if it hasn't already occurred. In this
341 context, it is critical that B/Yamagata detections captured by surveillance systems or studies
342 around the world within the context of research projects are properly investigated to determine
343 whether B/Yamagata cases are wild- or vaccine-derived virus detections, and that a much larger
344 proportion of influenza B detections are tested to determine their lineage. Vaccine-derived
345 detections can mostly be linked to sampling LAIV vaccinated individuals and indeed, several
346 B/Yamagata viruses whose sequences are uploaded in GISAID appeared to be vaccine-derived. It
347 is therefore important sequencing of influenza B viruses is encouraged and supported and that
348 procedures are put in place to assess the true circulation of the wild-type B/Yamagata virus, with
349 detailed virological (sequence confirmation) and epidemiological (i.e. vaccination status, timing
350 of vaccination and vaccine type) data being collected and shared (e.g. with the WHO and the
351 WHO Collaborating Centres).

352 Aside from the question of whether B/Yamagata viruses have or have not already become
353 extinct, the current epidemiological situation calls for a rapid response in terms of influenza
354 prevention practices. In particular, a decision needs to be made regarding as to whether QIVs

355 should be changed to TIVs and, if so, whether this change should be applied simultaneously to
356 both egg-based vaccines and LAIVs. Any decision in this regard would have regulatory and
357 manufacturing implications which would require different timescales to be implemented.
358 Importantly from a public health perspective, it is critical that countries are not confronted with a
359 situation where there are influenza vaccines shortages, thus these decisions would need to be
360 taken with care and in a coordinated manner. Also, concerns exist about how the change from
361 QIV to TIV should be communicated, as this could be confusing for the general public and have
362 a negative impact on national influenza vaccination campaigns. Perhaps more theoretically (as
363 implementation would be less immediate), the option of maintaining a quadrivalent vaccine by
364 removing the B/Yamagata virus strain and replacing it with another strain (e.g. two H3N2
365 strains) would be worth discussing. Of note, there are other issues that are important beyond
366 those concerning vaccine formulation and development. In particular, if B/Yamagata viruses are
367 considered extinct, the question arises as to whether influenza laboratories around the world
368 should change the security level with which they are allowed to handle B/Yamagata viruses, due
369 to the potential risks associated with the escape of an extinct influenza virus.

370 A few aspects relating to the sources of information that we researched deserve comment.
371 The WHO-FluNet database is dynamic in that the data it contains can change over time. For
372 example, a NIC or reference laboratory in a given country may need to make corrections to data
373 entered in previous weeks. As far as our current research question is concerned, it is worth noting
374 that the WHO-FluNet database does not presently have an option to report vaccine-derived
375 detections separately. We are aware that WHO proactively investigates all reports of B/Yamagata
376 entered into their global surveillance databases and these are sometimes removed at a later stage
377 when laboratory analyses reveal that they are vaccine-derived. In preparing this article, the 2020-

378 2023 data from the WHO-FluNet database were downloaded twice, on May 19th and then again
379 on August 28th 2023. In this short time period, the number of reported B/Yamagata influenza
380 cases decreased from 45 to 42 for the year 2021, and from 8 to 3 for the year 2022. Hence,
381 although the number of B/Yamagata detections in 2023, as shown in Table 2, slightly exceeded
382 the number in 2022 (6 vs. 3), this might be an overestimate compared to reality (and the same
383 considerations may apply to the GISAID database). A further limitation is the under-
384 representation of tropical countries, particularly in populous South-East Asia and Africa, in data
385 gathered from the review of scientific literature and webpages of respiratory viruses' surveillance
386 systems. This is important as we have previously shown that influenza B tended to circulate
387 more intensely in the tropics than in the temperate countries before the COVID-19 pandemic
388 [Caini 2019]. While a main strength of our data review is the systematic and comprehensive
389 nature of the exercise, one should recognise the limitations and shortcomings of the information
390 sources that we researched in order to be able to critically appraise the whole body of evidence
391 currently available on this topic.

392 We have described the current epidemiological situation regarding B/Yamagata lineage
393 viruses, and outlined its most important public health implications, particularly with regard to the
394 composition of influenza vaccines. A further, and currently overlooked source of uncertainty
395 with implications for immunization campaigns, relates to the timing of influenza epidemics in
396 the coming years [Caini 2018]. Right now, there is in fact no guarantee that the pre-pandemic
397 timing will be restored, or if instead, the co-circulation of SARS-CoV-2 will cause influenza
398 epidemics to be shifted by a few weeks earlier or later due to viral interference [Fage 2022, Piret
399 2022], which might in turn entail the need to accommodate the timing of vaccine strains
400 selection, manufacturing, and deployment. Furthermore, it is currently difficult to make

401 predictions about the impact that the disappearance of B/Yamagata viruses will have on the
402 circulation of other influenza viruses. B/Yamagata viruses tended to infect adults and the elderly
403 more often than those of the B/Victoria lineage, which are to a much larger extent limited to
404 children and adolescents [Caini 2019]. If B/Yamagata viruses actually became extinct, the age
405 distribution of influenza B cases might shift towards younger ages, thus resulting in a lower
406 disease burden than in the pre-COVID-19 era. However, this is currently nothing more than a
407 plausible hypothesis that only time will allow one to confirm or refute. These many uncertainties
408 imply that the role of epidemiological and virological monitoring of influenza viruses, SARS-
409 CoV-2, and the other respiratory viruses in protecting the health of populations is presently more
410 important than ever and will remain so for many years to come. In conclusion, international and
411 national public health authorities (both public health institutes and medical regulatory
412 authorities) are confronted with an unprecedented situation with the rapid disappearance and
413 potential extinction of the influenza B/Yamagata virus (a development they have not experienced
414 in the last 30 years) and need to take important decisions regarding influenza vaccines and the
415 B/Yamagata virus, and we believe this review will contribute to this decision-making process.

416

417

418 **Acknowledgments**

419 We would like to thank investigators at all sites participating to the Global Influenza Hospital
420 Surveillance Network (GIHSN).

421

422 **Funding statement**

423 Saverio Caini, Adam Meijer, Laetitia Henaff and Malaika Zounon received no specific finding
424 for this work. John Paget, Marco Del Riccio and Bronke Boudewijns were funded via a research
425 grant from Sanofi to NIVEL (FluCov project). Marta Nunes was funded via a research grant
426 from Sanofi to CERP.

427

DRAFT

428

429 **References**

- 430 1. Dhanasekaran V, Sullivan S, Edwards KM, Xie R, Khvorov A, Valkenburg SA, Cowling
431 BJ, Barr IG. Human seasonal influenza under COVID-19 and the potential consequences
432 of influenza lineage elimination. *Nat Commun.* 2022 Mar 31;13(1):1721. doi:
433 10.1038/s41467-022-29402-5.
- 434 2. Olsen SJ, Azziz-Baumgartner E, Budd AP, Brammer L, Sullivan S, Pineda RF, Cohen C,
435 Fry AM. Decreased Influenza Activity During the COVID-19 Pandemic - United States,
436 Australia, Chile, and South Africa, 2020. *MMWR Morb Mortal Wkly Rep.* 2020 Sep
437 18;69(37):1305-1309. doi: 10.15585/mmwr.mm6937a6.
- 438 3. Merced-Morales A, Daly P, Abd Elal AI, Ajayi N, Annan E, Budd A, Barnes J, Colon A,
439 Cummings CN, Iuliano AD, DaSilva J, Dempster N, Garg S, Gubareva L, Hawkins D,
440 Howa A, Huang S, Kirby M, Kniss K, Kondor R, Liddell J, Moon S, Nguyen HT,
441 O'Halloran A, Smith C, Stark T, Tastad K, Ujamaa D, Wentworth DE, Fry AM, Dugan
442 VG, Brammer L. Influenza Activity and Composition of the 2022-23 Influenza Vaccine -
443 United States, 2021-22 Season. *MMWR Morb Mortal Wkly Rep.* 2022 Jul
444 22;71(29):913-919. doi: 10.15585/mmwr.mm7129a1.
- 445 4. Puzelli S, Di Martino A, Facchini M, Fabiani C, Calzoletti L, Di Mario G, Palmieri A,
446 Affanni P, Camilloni B, Chironna M, D'Agaro P, Gianecchini S, Pariani E, Serra C,
447 Rizzo C, Bella A, Donatelli I, Castrucci MR; Italian Influenza Laboratory Network. Co-
448 circulation of the two influenza B lineages during 13 consecutive influenza surveillance
449 seasons in Italy, 2004-2017. *BMC Infect Dis.* 2019 Nov 21;19(1):990. doi:
450 10.1186/s12879-019-4621-z.

- 451 5. Zanobini P, Bonaccorsi G, Lorini C, Haag M, McGovern I, Paget J, Caini S. Global
452 patterns of seasonal influenza activity, duration of activity and virus (sub)type circulation
453 from 2010 to 2020. *Influenza Other Respir Viruses*. 2022 Jul;16(4):696-706. doi:
454 10.1111/irv.12969.
- 455 6. Koutsakos M, Wheatley AK, Laurie K, Kent SJ, Rockman S. Influenza lineage extinction
456 during the COVID-19 pandemic? *Nat Rev Microbiol*. 2021 Dec;19(12):741-742. doi:
457 10.1038/s41579-021-00642-4.
- 458 7. Paget J, Caini S, Del Riccio M, van Waarden W, Meijer A. Has influenza B/Yamagata
459 become extinct and what implications might this have for quadrivalent influenza
460 vaccines? *Euro Surveill*. 2022 Sep;27(39):2200753. doi: 10.2807/1560-
461 7917.ES.2022.27.39.2200753.
- 462 8. Xu C, Chan KH, Tsang TK, Fang VJ, Fung RO, Ip DK, Cauchemez S, Leung GM, Peiris
463 JS, Cowling BJ. Comparative Epidemiology of Influenza B Yamagata- and Victoria-
464 Lineage Viruses in Households. *Am J Epidemiol*. 2015 Oct 15;182(8):705-13. doi:
465 10.1093/aje/kwv110.
- 466 9. Dudas G, Bedford T, Lycett S, Rambaut A. Reassortment between influenza B lineages
467 and the emergence of a coadapted PB1-PB2-HA gene complex. *Mol Biol Evol*. 2015
468 Jan;32(1):162-72. doi: 10.1093/molbev/msu287.
- 469 10. Vesikari T, Karvonen A, Korhonen T, Edelman K, Vainionpää R, Salmi A, Saville MK,
470 Cho I, Razmpour A, Rappaport R, O'Neill R, Georgiu A, Gruber W, Mendelman PM,
471 Forrest B; CAIV-T Transmission Study Group. A randomized, double-blind study of the
472 safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza

- 473 virus vaccine. *Pediatr Infect Dis J*. 2006 Jul;25(7):590-5. doi:
474 10.1097/01.inf.0000220229.51531.47.
- 475 11. Soldevila N, Basile L, Martínez A, Torner N, Marcos MÁ, Mosquera MDM, Antón A,
476 Andrés C, Rius C, Pumarola T, Domínguez Á; the PIDIRAC Surveillance of Hospitalized
477 Cases of Severe Influenza in Catalonia Working Group. Surveillance of influenza B
478 severe hospitalized cases during 10 seasons in Catalonia: Does the lineage make a
479 difference? *J Med Virol*. 2022 Sep;94(9):4417-4424. doi: 10.1002/jmv.27876.
- 480 12. Murillo-Zamora E, Trujillo X, Huerta M, Ríos-Silva M, Guzmán-Esquivel J, Benites-
481 Godínez V, Mendoza-Cano O. Survival in influenza virus-related pneumonia by viral
482 subtype: 2016-2020. *Int J Infect Dis*. 2021 Nov;112:288-293. doi:
483 10.1016/j.ijid.2021.09.037.
- 484 13. Korsun N, Trifonova I, Voleva S, Grigorova I, Angelova S. Genetic characterisation of
485 the influenza viruses circulating in Bulgaria during the 2019-2020 winter season. *Virus*
486 *Genes*. 2021 Oct;57(5):401-412. doi: 10.1007/s11262-021-01853-w.
- 487 14. Panatto D, Orsi A, Pennati BM, Lai PL, Mosca S, Bruzzone B, Caligiuri P, Napoli C,
488 Bertamino E, Orsi GB, Manini I, Loconsole D, Centrone F, Pandolfi E, Ciofi Degli Atti
489 ML, Concato C, Linardos G, Onetti Muda A, Raponi M, Piccioni L, Rizzo C, Chironna
490 M, Icardi G. No evidence of SARS-CoV-2 in hospitalized patients with severe acute
491 respiratory syndrome in five Italian hospitals from 1st November 2019 to 29th February
492 2020. *PLoS One*. 2021 Dec 7;16(12):e0260947. doi: 10.1371/journal.pone.0260947.
- 493 15. Pablo-Marcos D, Rodríguez-Fernández A, Gozalo M, Agüero J, Arnaiz de Las Revillas F,
494 Calvo J. Descripción de la epidemia estacional por Gripe B en Cantabria durante los
495 inicios de la pandemia por SARS-CoV-2 [Description of Influenza B in seasonal

- 496 epidemic in Cantabria during the beginning of the pandemia due to SARS-CoV-2]. Rev
497 Esp Quimioter. 2020 Dec;33(6):444-447. Spanish. doi: 10.37201/req/077.2020.
- 498 16. Miron VD, Bănică L, Săndulescu O, Paraschiv S, Surleac M, Florea D, Vlaicu O, Milu P,
499 Streinu-Cercel A, Bilașco A, Oțelea D, Pițigoi D, Streinu-Cercel A, Drăgănescu AC.
500 Clinical and molecular epidemiology of influenza viruses from Romanian patients
501 hospitalized during the 2019/20 season. PLoS One. 2021 Nov 12;16(11):e0258798. doi:
502 10.1371/journal.pone.0258798.
- 503 17. Hu W, Gruner WE, DeMarcus LS, Thervil JW, Kwaah B, Fries AC, Sjoberg PA, Robbins
504 AS. Influenza Surveillance Trends and Influenza Vaccine Effectiveness Among
505 Department of Defense Beneficiaries During the 2019-2020 Influenza Season. MSMR.
506 2021 Mar;28(3):2-8.
- 507 18. Omer I, Rosenberg A, Sefty H, Pando R, Mandelboim M, Mendelson E, Keinan-Boker L,
508 Glatman-Freedman A; Israel Influenza Surveillance Network (IISN). Lineage-matched
509 versus mismatched influenza B vaccine effectiveness following seasons of marginal
510 influenza B circulation. Vaccine. 2022 Feb 7;40(6):880-885. doi:
511 10.1016/j.vaccine.2021.12.056.
- 512 19. Olson SM, Newhams MM, Halasa NB, Feldstein LR, Novak T, Weiss SL, Coates BM,
513 Schuster JE, Schwarz AJ, Maddux AB, Hall MW, Nofziger RA, Flori HR, Gertz SJ, Kong
514 M, Sanders RC, Irby K, Hume JR, Cullimore ML, Shein SL, Thomas NJ, Stewart LS,
515 Barnes JR, Patel MM, Randolph AG; Pediatric Intensive Care Influenza Investigators.
516 Vaccine Effectiveness Against Life-Threatening Influenza Illness in US Children. Clin
517 Infect Dis. 2022 Aug 25;75(2):230-238. doi: 10.1093/cid/ciab931.

- 518 20. Auvinen R, Syrjänen R, Ollgren J, Nohynek H, Skogberg K. Clinical characteristics and
519 population-based attack rates of respiratory syncytial virus versus influenza
520 hospitalizations among adults-An observational study. *Influenza Other Respir Viruses*.
521 2022 Mar;16(2):276-288. doi: 10.1111/irv.12914.
- 522 21. Kuzmanovska M, Boshevska G, Janchevska E, Buzharova T, Simova M, Peshnacka A,
523 Nikolovska G, Kochinski D, Ilioska RS, Stavridis K, Mikikj V, Kuzmanovska G, Memeti
524 S, Gjorgoski I. A Comprehensive Molecular and Epidemiological Characterization of
525 Influenza Viruses Circulating 2016-2020 in North Macedonia. *Front Microbiol*. 2021 Oct
526 21;12:713408. doi: 10.3389/fmicb.2021.713408.
- 527 22. Wagatsuma K, Saito R, Chon I, Phyu WW, Fujio K, Kawashima T, Sato I, Saito T,
528 Minato M, Kodo N, Suzuki E, Ono Y, Masaki H, Shirahige Y, Kitano A, Hamabata H,
529 Yuyang S, Jiaming L, Watanabe H. Duration of fever and symptoms in influenza-infected
530 children treated with baloxavir marboxil during the 2019-2020 season in Japan and
531 detection of influenza virus with the PA E23K substitution. *Antiviral Res*. 2022
532 May;201:105310. doi: 10.1016/j.antiviral.2022.105310.
- 533 23. Heinzinger S, Eberle U, Angermeier H, Flechsler J, Konrad R, Dangel A, Berger C,
534 Sprenger A, Hepner S, Biere B, Liebl B, Ackermann N, Sing A. Reciprocal circulation
535 pattern of SARS-CoV-2 and influenza viruses during the influenza seasons 2019/2020
536 and 2020/2021 in the Bavarian Influenza Sentinel (Germany). *Epidemiol Infect*. 2021 Oct
537 26;149:e226. doi: 10.1017/S0950268821002296. Erratum in: *Epidemiol Infect*. 2022 Feb
538 11;150:e24.
- 539 24. Ríos-Silva M, Trujillo X, Huerta M, Benites-Godínez V, Guzmán-Esquivel J, Bricio-
540 Barrios JA, Mendoza-Cano O, Lugo-Radillo A, Murillo-Zamora E. Reemerging

- 541 Influenza Virus Infections during the Dominance of the Omicron SARS-CoV-2 Variant in
542 Mexico. *Pathogens*. 2022 Oct 13;11(10):1181. doi: 10.3390/pathogens11101181.
- 543 25. Suntronwong N, Klinfueng S, Korkong S, Vichaiwattana P, Thongmee T, Vongpunsawad
544 S, Poovorawan Y. Characterizing genetic and antigenic divergence from vaccine strain of
545 influenza A and B viruses circulating in Thailand, 2017-2020. *Sci Rep*. 2021 Jan
546 12;11(1):735. doi: 10.1038/s41598-020-80895-w.
- 547 26. Costa JCD, Siqueira MM, Brown D, Lopes JO, Costa BCD, Gama EL, Aguiar-Oliveira
548 ML. Vaccine Mismatches, Viral Circulation, and Clinical Severity Patterns of Influenza B
549 Victoria and Yamagata Infections in Brazil over the Decade 2010-2020: A Statistical and
550 Phylogeny-Trait Analyses. *Viruses*. 2022 Jul 5;14(7):1477. doi: 10.3390/v14071477.
- 551 27. Melidou A, Pereyaslov D, Hungnes O, Prosenc K, Alm E, Adlhoch C, Fielding J,
552 Sneiderman M, Martinuka O, Celentano LP, Pebody R; WHO European Region influenza
553 surveillance network; WHO European Region Influenza Surveillance Network author
554 list. Virological surveillance of influenza viruses in the WHO European Region in
555 2019/20 - impact of the COVID-19 pandemic. *Euro Surveill*. 2020 Nov;25(46):2001822.
556 doi: 10.2807/1560-7917.ES.2020.25.46.2001822.
- 557 28. Huang WJ, Cheng YH, Tan MJ, Liu J, Li XY, Zeng XX, Tang J, Wei HJ, Chen T, Yang L,
558 Xie YR, Yang JY, Xiao N, Wang DY. Epidemiological and virological surveillance of
559 influenza viruses in China during 2020-2021. *Infect Dis Poverty*. 2022 Jun 29;11(1):74.
560 doi: 10.1186/s40249-022-01002-x
- 561 29. O'Neill G, Aziz A, Kuba M, Brown SK, Lau H, Soppe S, Baz M, Peck H, Deng YM,
562 Subbarao K, Barr IG. Report on influenza viruses received and tested by the Melbourne

- 563 WHO Collaborating Centre for Reference and Research on Influenza during 2020-2021.
564 *Commun Dis Intell* (2018). 2022 Sep 26;46. doi: 10.33321/cdi.2022.46.63.
- 565 30. Kolosova NP, Ilyicheva TN, Svyatchenko SV, Danilenko AV, Onkhonova GS, Ivanova
566 KI, Susloparov IM, Ryzhikov AB. Initial and severe cases of influenza in 2020-2022 and
567 population immunity prior to epidemic season. *Medical Immunology (Russia)*.
568 2022;24(6):1219-1226. Russian. doi: 10.15789/1563-0625-IAS-2513.
- 569 31. Peck H, Anbumurali N, McMahon K, Freeman K, Aziz A, Gillespie L, Yang B, Moselen
570 J, Deng YM, Cowling BJ, Barr IG, Subbarao K, Sullivan SG. Detection of Influenza in
571 Managed Quarantine in Australia and the Estimated Risk of Importation. *Clin Infect Dis*.
572 2023 Feb 8;76(3):e1328-e1334. doi: 10.1093/cid/ciac648.
- 573 32. Chon I, Saito R, Kyaw Y, Aye MM, Setk S, Phyu WW, Wagatsuma K, Li J, Sun Y,
574 Otaguro T, Win SMK, Yoshioka S, Win NC, Ja LD, Tin HH, Watanabe H. Whole-
575 Genome Analysis of Influenza A(H3N2) and B/Victoria Viruses Detected in Myanmar
576 during the COVID-19 Pandemic in 2021. *Viruses*. 2023 Feb 20;15(2):583. doi:
577 10.3390/v15020583.
- 578 33. Melidou A, Ködmön C, Nahapetyan K, Kraus A, Alm E, Adlhoch C, Mooks P, Dave N,
579 Carvalho C, Meslé MM, Daniels R, Pebody R; Members of the WHO European Region
580 influenza surveillance network; Members of the WHO European Region influenza
581 surveillance network that contributed virus characterisation data. Influenza returns with a
582 season dominated by clade 3C.2a1b.2a.2 A(H3N2) viruses, WHO European Region,
583 2021/22. *Euro Surveill*. 2022 Apr;27(15):2200255. doi: 10.2807/1560-
584 7917.ES.2022.27.15.2200255.

- 585 34. Sominina A, Danilenko D, Komissarov A, Karpova L, Pisareva M, Fadeev A,
586 Konovalova N, Eroptin M, Stolyarov K, Shtro A, Burtseva E, Lioznov D. Resurgence of
587 Influenza Circulation in the Russian Federation during the Delta and Omicron COVID-19
588 Era. *Viruses*. 2022 Aug 29;14(9):1909. doi: 10.3390/v14091909.
- 589 35. Song SX, Sun L, He YJ, Wu JL, Sun WK, Zhang S, Li Z, Kou ZQ, Liu T. [Analysis of
590 the epidemiological characteristics and genetic characteristics of influenza in the
591 surveillance-year of 2021 to 2022 in Shandong Province, China]. *Zhonghua Yu Fang Yi*
592 *Xue Za Zhi*. 2022 Nov 6;56(11):1554-1559. Chinese. doi: 10.3760/cma.j.cn112150-
593 20220812-00807.
- 594 36. Aslam S, Rajendran M, Kriti D, Kurland A, Johnson J, van Bakel H, Krammer F, García-
595 Sastre A, Ayllon J. Generation of a high yield vaccine backbone for influenza B virus in
596 embryonated chicken eggs. *NPJ Vaccines*. 2023 Feb 10;8(1):12. doi: 10.1038/s41541-
597 023-00603-3.
- 598 37. Xu C, Chan KH, Tsang TK, Fang VJ, Fung RO, Ip DK, Cauchemez S, Leung GM, Peiris
599 JS, Cowling BJ. Comparative Epidemiology of Influenza B Yamagata- and Victoria-
600 Lineage Viruses in Households. *Am J Epidemiol*. 2015 Oct 15;182(8):705-13. doi:
601 10.1093/aje/kwv110.
- 602 38. Ikonen N, Pyhälä R, Axelin T, Kleemola M, Korpela H. Reappearance of influenza
603 B/Victoria/2/87-lineage viruses: epidemic activity, genetic diversity and vaccination
604 efficacy in the Finnish Defence Forces. *Epidemiol Infect*. 2005 Apr;133(2):263-71. doi:
605 10.1017/s0950268804003462.
- 606 39. Caini S, Kuszniarz G, Garate VV, Wangchuk S, Thapa B, de Paula Júnior FJ, Ferreira de
607 Almeida WA, Njouom R, Fasce RA, Bustos P, Feng L, Peng Z, Araya JL, Bruno A, de

- 608 Mora D, Barahona de Gámez MJ, Pebody R, Zambon M, Higueros R, Rivera R, Kosasih
609 H, Castrucci MR, Bella A, Kadjo HA, Daouda C, Makusheva A, Bessonova O, Chaves
610 SS, Emukule GO, Heraud JM, Razanajatovo NH, Barakat A, El Falaki F, Meijer A,
611 Donker GA, Huang QS, Wood T, Balmaseda A, Palekar R, Arévalo BM, Rodrigues AP,
612 Guiomar R, Lee VJM, Ang LW, Cohen C, Treurnicht F, Mironenko A, Holubka O, Bresee
613 J, Brammer L, Le MTQ, Hoang PVM, El Guerche-Séblain C, Paget J; Global Influenza B
614 Study team. The epidemiological signature of influenza B virus and its B/Victoria and
615 B/Yamagata lineages in the 21st century. *PLoS One*. 2019 Sep 12;14(9):e0222381. doi:
616 10.1371/journal.pone.0222381.
- 617 40. Caini S, Schellevis F, El-Guerche Séblain C, Paget J. Important changes in the timing of
618 influenza epidemics in the WHO European Region over the past 20 years: virological
619 surveillance 1996 to 2016. *Euro Surveill*. 2018 Jan;23(1):17-00302. doi: 10.2807/1560-
620 7917.ES.2018.23.1.17-00302.
- 621 41. Fage C, Hénaut M, Carbonneau J, Piret J, Boivin G. Influenza A(H1N1)pdm09 Virus but
622 Not Respiratory Syncytial Virus Interferes with SARS-CoV-2 Replication during
623 Sequential Infections in Human Nasal Epithelial Cells. *Viruses*. 2022 Feb 15;14(2):395.
624 doi: 10.3390/v14020395.
- 625 42. Piret J, Boivin G. Viral Interference between Respiratory Viruses. *Emerg Infect Dis*. 2022
626 Feb;28(2):273-281. doi: 10.3201/eid2802.211727.

627

628 **Table 1.** Literature review of articles reporting on the number of influenza B/Yamagata virus detections from January 1st, 2020.

Author, year	Country or world region	Start of observation period	End of observation period	N respiratory specimens	N influenza	N influenza B	N influenza B characterized	N influenza B Yamagata
<i>Observation period from <u>before 2019</u> to <u>2020</u></i>								
Soldevila N et al, 2022 ^(a)	Spain	2010, ns	2020, ns	NA	NA	NA	1,159	955
Murillo-Zamora E et al, 2021	Mexico	2016, Oct	2020, Apr	NA	4,678	808	632	283
<i>Observation period from <u>2019</u> to <u>2020</u></i>								
Korsun N et al, 2021	Bulgaria	2019, Oct	2020, Mar	1,387	610	138	138	0
Panatto D et al, 2021	Italy	2019, Nov	2020, Feb	1,683	477	119	53	1
Pablo-Marcos D et al, 2020	Spain	2019, Nov	2020, Mar	NA	652	180	167	0
Miron VD et al, 2021	Romania	2019, Nov	2020, Mar	1,042	516	244	239	0
Hu W et al, 2021	USA	2019, w45	2020, w13	28,176	5,529	2,336	862	6
Omer I et al, 2022	Israel	2019, w46	2020, w11	1,769	973	354	NA	0
Olson SM et al, 2022	USA	2019, Dec	2020, Apr	291	159	61	39	0
Auvinen R et al, 2022	Finland	2019, Dec	2020, Jun	244	33	2	2	0
Kuzmanovska M et al, 2021 ^(a)	Macedonia	2019, ns	2020, ns	NA	251	NA	NA	0
Wagatsuma K et al, 2022 ^(a)	Japan	2019, ns	2020, ns	NA	159	53	53	0
<i>Observation period from <u>2019</u> to <u>2021</u> or <u>2022</u></i>								

Heinzinger S et al, 2021	Germany	2019, w38	2020, w14	1,376	517	153	151	22
		2020, w38	2021, w14	470	3	1	1	0
Ríos-Silva M et al, 2022	Mexico	2019, Oct	2020, Apr	NA	4,836	1,910	1,843	92
		2020, Oct	2021, Apr	NA	0	-	-	-
		2021, Oct	2022, Apr	NA	816	7	4	0
<i>Observation period entirely in 2020</i>								
Suntronwong N et al, 2021	Thailand	2020, Jan	2020, Mar	NA	349	NA	NA	0
da Costa JC et al, 2022	Brazil	2020, Jan	2020, Mar	NA	NA	9	9	0
Melidou A et al, 2020	WHO Euro	2020, w1	2020, w20	NA	1,691	397	397	1
<i>Observation period from 2020 to 2021 or 2022</i>								
Huang WJ et al, 2022	Northern China	2020, Jan	2020, Dec	177,987	11,742	2,100	2,093	42
		2021, Jan	2021, Dec	220,011	12,117	12,106	12,087	13
	Southern China	2020, Jan	2020, Dec	294,656	14,698	6,817	6,719	15
		2021, Jan	2021, Dec	336,851	25,227	25,163	24,966	13
O'Neill G et al, 2022	Melbourne WHO-CCRI	2020, Jan	2020, Dec	NA	2,021	NA	65	2
		2021, Jan	2021, Dec	NA	372	NA	13	0
Kolosova NP et al, 2022	Russia	2020, Mar	2021, May	NA	6	6	6	0
		2021, Jun	2022, Feb	NA	920	17	12	0

<i>Observation period in <u>2021</u> or from <u>2021 to 2022</u></i>								
Peck H et al, 2023	Australia	2021, Jan	2021, Oct	15,026 ^(b)	42	10	10	0
Chon I et al, 2023	Myanmar	2021, Oct	2021, Dec	414	16	3	3	0
Merced-Morales A et al, 2022	USA	2021, Oct	2022, Jun	877,928	24,432	126	41	1 ^(c)
Melidou A et al, 2022	WHO Euro	2021, w40	2022, w10	NA	55,049	1,603	15	7 ^(d)
Sominina A et al, 2022 ^(a)	Russia	2021, ns	2022, ns	137,161	8,637	275	275	0
Song SX et al, 2022 ^(a)	China	2021, ns	2022, ns	26,754	7,250	7,250	7,250	0

629

630 N: number of reported cases. WHO-CCRI: World Health Organization - Collaborating Centre for Reference and Research on Influenza

631 ^(a) The observation period was reported as the "season" (namely, the season 2019-2020 in Kuzmanovska et al. and Wagatsuma et al.; the season 2021-2022 in
632 Sominina et al. and Song et al.; and the seasons 2010-2020 in Soldevila et al.).

633 ^(b) The specimens were collected from travellers arriving on repatriation flights..

634 ^(c) Other B/Yamagata detections were linked to LAIV, while only 1 was not tested.

635 ^(d) All reported 7 B/Yamagata were from Scotland and coincided with LAIV vaccination campaign, but further testing was not performed

636 **Table 2.** WHO-FluNet: number of influenza B Yamagata detections (overall and by country) in 2020 (weeks 1-17 or 18-53), 2021,
637 2022, and 2023 until week 19, and rate of detections per 100,000 processed specimens and influenza-, influenza B-, and characterized
638 influenza B-positive detections.

Year and period	Influenza B Yamagata detections	Influenza B Yamagata detections per 100,000:				Detections by country and week
		processed specimens ^(a)	influenza-positive detections	influenza B-positive detections	influenza B-positive detections, lineage characterized	
2020, weeks 1-17	351	14.88	75.27	211.54	1386.47	n = 117: USA (weeks 1-13), n = 67: Mexico (weeks 1-14), n = 54: China (weeks 1-17), n = 18: Norway (weeks 1-8), n = 14: Dominican Republic (weeks 2-9), n = 10: France (weeks 2-12), n < 10: 24 countries
2020, weeks 18-52	13	0.40	269.93	604.09	2245.25	n = 8: USA (weeks 44-49), n = 4: China (weeks 19-51), n = 1: Afghanistan (week 45)
2021	42	0.51	36.10	123.55	144.33	n = 32: China (weeks 1-39), n = 3: India (week 41), n = 1: Afghanistan (week 1), Niger (week 1), Ghana (week 4), Bulgaria (week 8), Ivory Coast (week 8), Mexico (week 24), USA (week 39)
2022	3	0.03	0.31	4.74	8.67	n = 2: Germany (weeks 12-13), n = 1: North Korea (week 43)
2023, weeks 1-33	6	0.09	1.40	5.25	33.61	n = 5: Cameroon (weeks 23-31), n = 1: Cuba (week 11)

639 ^(a) Calculated over the total of countries and weeks in which the number of processed specimens was reported.

640 **Table 3.** Global Influenza Hospital Surveillance Network: number of influenza detections (overall, type B, characterized type B, and
 641 B/Yamagata) in 2020 (weeks 1-17 or 18-53), 2021, 2022, and 2023 until week 29.

Period	Influenza-positive detections	Influenza B-positive detections	Influenza B-positive detections, lineage characterized	Influenza B/Yamagata detections by country and week
2020, weeks 1-17	3,772	1,449	639	6 (France weeks 1 and 9, India week 5, Mexico weeks 6 and 9, Russia week 12)
2020, weeks 18-53	15	5	1	1 (India week 51)
2021	875	149	33	0
2022	2,961	241	173	0
2023, weeks 1-27	967	211	132	0

642


643 **Table 4.** Number of respiratory specimens tested for influenza, and number of reported influenza B/Yamagata detections, from
 644 national influenza surveillance systems webpages worldwide (see text for a complete list of countries that were included).

Year and period	Influenza B Yamagata detections	Detections by country and week	Influenza positive specimens by country and surveillance system
2019, week 40 to 2020, week 20	n = 269	<p>n=1 : Spain (week 1/2020), Netherlands (week 8/2020), England (week 6/2020), Portugal (week 48/2019), Russia (week 05/2020), Germany, (unknown week)</p> <p>n=239 : USA (weeks 40/2019 to 13/2020)</p> <p>n=24 : France (weeks 48/2019 to 11/2020)</p>	<p>n=2,579 : Spain (Virus characterisation)</p> <p>n=207 : Netherland (GP surveillance)</p> <p>n=1,204 : England (Virus characterisation)</p> <p>n=303 : Germany (Virus characterisation)</p> <p>n=349 : Portugal (emergency and obstetrics wards)</p> <p>n=16,649 : Russia (National Influenza Centres and network of Regional Base Laboratories)</p> <p>n=45,898 : USA (Public Health Laboratories)</p> <p>n=1,195 : France (GP surveillance)</p>
2020, week 35 to 2021, week 39	n = 10	<p>n=1 : Australia (week 37-38/2020)</p> <p>n=9 : USA (weeks 44-49/2020, 39/2021)</p>	<p>n=306 : Australia (World Health Organization Collaborating Centre for Reference and Research on Influenza)</p> <p>n=352 : USA (Public Health Laboratories)</p>
2021, week 40 to 2022, week 39	n = 1	n=1 : USA (week 46/2021)	n=26,322 : USA (Public Health Laboratories)

645 GP: general practitioners

646 **Figure 1.** Flow-chart of the systematic literature review of articles reporting the number of
647 influenza B/Yamagata virus detections from January 1st, 2020, until March 20th, 2023.


648



649



650 **Figure 2.** Map depicting the countries in which the last reported B/Yamagata detection occurred in 2023, 2022, 2021, or 2020 or
651 before.



652